Medically reviewed by Femi Aremu, PharmD Ozempic and Wegovy are both glucagon-like peptide-1 (GLP-1) receptor agonists and contain the active ingredient semaglutide. They share many similarities, and both effectively lower cardiovascular risk.

In the years leading up to its bankruptcy filing, the company also struggled with the growth of free or low-cost fitness-related social media content and diet-based smartphone apps.

Ozempic is massively threatening the established diet industry — and it appears that Weight Watchers is now getting the hatchet.